XyloCor Therapeutics

King of Prussia, PA · Founded 2013 · Privately Held (backing)

Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. XyloCor Therapeutics is based in King of Prussia, PA and was founded in 2013. It was valued at $130 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $122 million across 3 recorded rounds; the latest was a $4 million seed round in Jan 2021.

PMV mark · valuation
$130.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$122.0M
Last round
Seed Round
Jan 2021
What is XyloCor Therapeutics worth?
$130.0MPrivateMarketView mark · Oct 2026

Valued at $130.0M at its later-stage round, Jan 2025. Nothing has traded since.

Free account
More of XyloCor Therapeutics with a free account
  • ·Watch XyloCor Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

XyloCor Therapeutics funding history

3 rounds
DateRoundRaisedPost-money
Jan 2021Seed Round$4.0M▮
Oct 2018Early Stage VC$16.8M▮
Nov 2016Debt$250K▮
Unlock post-money valuations

Membership and data by Private Market View

XyloCor Therapeutics valuation

XyloCor Therapeutics was valued at $130 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has XyloCor Therapeutics raised?

XyloCor Therapeutics has raised $122 million in total; 3 of its rounds are on record, from 2016 on. The largest on record was a $4 million seed round in Jan 2021.

XyloCor Therapeutics has filed 6 Form Ds with the SEC since 2016, most recently in Jan 2021 ($4 million sold to 5 investors).

How XyloCor Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For XyloCor Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about XyloCor Therapeutics

What is XyloCor Therapeutics worth?
XyloCor Therapeutics is valued at $130.0M as of Oct 2026. Valued at $130.0M at its later-stage round, Jan 2025. Nothing has traded since.
How much has XyloCor Therapeutics raised?
XyloCor Therapeutics has raised $122.0M in total funding across 3 recorded rounds.
When did XyloCor Therapeutics last raise?
XyloCor Therapeutics last raised in Jan 2021 (Seed Round), raising $4.0M.